Latest News and Events
Filter by
Selections
June 21, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
Read MoreJune 3, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
Read MoreApril 28, 2021
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
Read MoreApril 15, 2021